Dermatology Reports · 2011 · 10 citations · 5 references
MedicineDermatologyOncologyChemotherapyCutaneous OncologyHypersensitivityCutaneous NeoplasmsDermatologic Toxicity ManagementDrug-induced Skin ReactionsHyperpigmentation TreatmentInflammatory DermatosesMucositis TreatmentChemotherapy Dose-limiting ToxicityChemotherapy-induced Dermatologic ToxicityCutaneous Adverse EventsDose-limiting Toxicity AssessmentLocalized HyperpigmentationPalmoplantar Keratoderma SyndromesSevere Cutaneous Adverse ReactionsSkin Hyperpigmentation
Tegafur is a prodrug of 5-fluorouracil (5-FU) with a similar spectrum of antitumor activity. It is used in the treatment of advanced gastrointestinal neoplasms. Over 5-FU, tegafur has the advantage of oral administration and less hematologic toxicity. Gastrointestinal toxicity is its main dose-limiting factor. The cutaneous adverse effects of tegafur include mucositis, photosensitivity, diffuse or nail-restricted hyperpigmentation, palmoplantar erythrodysesthesia syndrome, palmoplantar keratoderma, sclerodactyly and Raynaud phenomenon. We report here the case of a patient who developed acral hyperpigmentation during treatment with tegafur.
5
Tegafur-induced acral hyperpigmentation.
Enric Llistosella, Ruth Álvarez, Ramón M. Pujol et al. · PubMed · 1991 · 33 citations
Medicine, Dermatology, Oncology +17